Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Human Gene Therapy|April 27, 2002
Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapyYamina Hamel, Neil Blake, Susanne Gabrielsson, et al.
Cancer Research|August 3, 2005
Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptorJianMin Lin, Alshad S Lalani, Thomas C Harding, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 12, 2025
Differential shaping of T cell responses elicited by heterologous ChAd68/self-amplifying mRNA SIV vaccine in macaques in combination with αCTLA4, αPD-1, or FLT3R agonistAmy R Rappaport, Elena Bekerman, Gregory R Boucher, et al.
Vaccine|July 5, 2025
Self-amplifying mRNA expressing COBRA hemagglutinin elicits long-lasting, broadly reactive antibodies against seasonal influenza A virusesSpencer R Pierce, Hua Shi, Camila Caetano, et al.
Journal for Immunotherapy of Cancer|July 22, 2015
Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumabSaskia Jam Santegoets, Anita Gm Stam, Sinéad M Lougheed, et al.
Nature Communications|June 7, 2022
Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infectionAmy R Rappaport, Sue-Jean Hong, Ciaran D Scallan, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 4, 2006
AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastomaThomas C Harding, Alshad S Lalani, Byron N Roberts, et al.
Science Immunology|July 20, 2022
Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic T<sub>reg</sub> reduction and effector T cell activationKim M van Pul, Jessica C L Notohardjo, Marieke F Fransen, et al.
Cancer Immunology, Immunotherapy : CII|August 11, 2012
T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatmentSaskia J A M Santegoets, Anita G M Stam, Sinéad M Lougheed, et al.
The Lancet. Oncology|February 14, 2012
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialAlfons J M van den Eertwegh, Jurjen Versluis, H Pieter van den Berg, et al.
Pageof 5